Literature DB >> 14534331

Minimal residual disease in chronic myeloid leukemia.

Bob Löwenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14534331     DOI： 10.1056/NEJMp038130

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.

Authors:  Dana Paquin; Peter S Kim; Peter P Lee; Doron Levy
Journal:  Bull Math Biol       Date:  2010-06-09       Impact factor: 1.758

2.  Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Gautam Borthakur; Farhad Ravandi; Srdan Verstovsek; Jianqin Shan; Jorge Cortes
Journal:  Haematologica       Date:  2011-02-28       Impact factor: 9.941

3.  Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

Authors:  Don L Gibbons; Sabrina Pricl; Paola Posocco; Erik Laurini; Maurizio Fermeglia; Hanshi Sun; Moshe Talpaz; Nicholas Donato; Alfonso Quintás-Cardama
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

Review 4.  Interpretation of cytogenetic and molecular results in patients treated for CML.

Authors:  Carlos E Vigil; Elizabeth A Griffiths; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2011-03-17       Impact factor: 8.250

5.  Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.

Authors:  Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Jody Hiteshew; Jenny Shan; Susan O'Brien; Hagop Kantarjian
Journal:  Cancer       Date:  2010-09-30       Impact factor: 6.860

6.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

Review 7.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

Review 8.  Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

Authors:  E K Thomas; J A Cancelas; Y Zheng; D A Williams
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528

Review 9.  MUC1 in hematological malignancies.

Authors:  Dina Stroopinsky; Donald Kufe; David Avigan
Journal:  Leuk Lymphoma       Date:  2016-06-27

10.  The CML stem cell: evolution of the progenitor.

Authors:  Scott A Stuart; Yosuke Minami; Jean Y J Wang
Journal:  Cell Cycle       Date:  2009-05-17       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.